Adenovirus infections are a frequent and serious complication following allogeneic haematopoietic stem cell transplantation (HSCT). The antiviral drugs cidofovir and ribavirin have been used as first-line therapy for disseminated infections with variable results. In the present study, in vitro susceptibility to these two drugs was evaluated on HEp-2 cells in adenovirus reference strains representing serotypes of each of the six species and in clinical isolates. Susceptibility to cidofovir was comparable between species with inhibition of replication of all tested serotypes in a narrow dose range (IC50= 17–81 μM). However, susceptibility to ribavirin was highly dependent on the species. Serotypes from species A, B, D, E and F were all resistant to ribavirin (IC50=396 to >500 μM). Only replication of serotypes from species C was inhibited by ribavirin (IC50=48–108 μM). This species-dependent susceptibility of adenovirus to ribavirin was confirmed in clinical isolates. When tested on other cell lines (PLC, A549 and 293), all species were revealed to be resistant to ribavirin. If our in vitro findings are predictive of virological responses in vivo, these results suggest that ribavirin would not be effective for management of non-C species adenovirus infections after HSCT.
References
1.
WallsT., ShankarA.G., & ShingadiaD.Adenovirus: an increasingly important pathogen in paediatric bone marrow transplant patients.Lancet Infectious Diseases2003; 3: 79–86.
2.
MiyamuraK., HamaguchiM., TajiH., KanieT., KohnoA., TanimotoM., SaitoH., KojimaS., MatsuyamaT., KitaoriK., NagafujiK., SatoT., & KoderaY.Successful ribavirin therapy for severe adenovirus hemorrhagic cystitis after allogeneic marrow transplant from close HLA donors rather than distant donors.Bone Marrow Transplantation2000; 25: 545–548.
3.
HoffmanJ.A., ShahA.J., RossL.A., & KapoorN.Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation.Biology Blood & Marrow Transplantation2001; 7: 388–394.
4.
BordigoniP., CarretA.S., VenardV., WitzF., & Le FaouA.Treatment of adenovirus infections in patients undergoing allogeneic haematopoietic stem cell transplantation.Clinical Infectious Diseases2001; 32: 1290–1297.
5.
LegrandF., BerrebiD., HouhouN., FreymuthF., FayeA., DuvalM., MougenotJ.F., PeuchmaurM., & VilmerE.Early diagnosis of adenovirus infection and treatment with cidofovir after bone marrow transplantation in children.Bone Marrow Transplantation2001; 27: 621–626.
6.
LjungmanP., RibaudP., EyrichM., Mathes-MartinS., EinseleH., BleakleyM., MachaczkaM., BieringsM., BosiA., GratecosN., & CordonnierC.Cidofovir for adenovirus infections after allogeneic haematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.Bone Marrow Transplantation2003; 31: 481–486.
7.
LankesterA.C., HeemskerkB., ClaasE.C.J., SchilhamM.W., BeersmaM.F.C., BrediusR.G.M., van TolM.J.D., & KroesA.C.M.Effect of ribavirin on the plasma viral DNA load in patients with disseminating adenovirus infection.Clinical Infectious Diseases2004; 38: 1521–1525.
8.
ChakrabartiS., MautnerV., OsmanH., CollinghamK.E., FeganC.D., KlapperP.E., MossP.A., & MilliganD.W.Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery.Blood2002; 100: 1619–1627.
9.
RomanowskiE.G., GordonY.J., Yaraullo-CruzT., YatesK.A., & KinchingtonP.R.The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model.Investigative Ophthalmology & Visual Science2001; 42: 1812–1815.
10.
LangloisM., AllardJ.P., NugierF., & AymardM.A rapid and automated colorimetric assay for evaluating the sensitivity of herpes simplex strains to antiviral drugs.Journal of Biological Standardization1986; 14: 201–211.
11.
WildnerO., HoffmannD., JoglerC., & UberlaK.Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of replication-competent adenoviral vectors by a panel of drugs.Cancer Gene Therapy2003; 10: 791–802.
12.
De OliveiraC.B.R., StevensonD., LaBreeL., McDonnellP.J., & TrousdaleM.D.Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.Antiviral Research1996; 31: 165–172.
13.
GordonY.J., RomanowskiE., Araullo-CruzT., SeabergL., ErzurumS., TolmanR., & de ClercqE.Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2′-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro.Antiviral Research1991; 16: 11–16.
14.
LjungmanP.Treatment of adenovirus infections in the immunocompromised host.European Journal of Clinical Microbiology & Infectious Diseases2004; 23: 583–588.
15.
AllenL.B., BoswellK.H., KhwajaT.A., MeyerR.B., SidwellR.W., & WitkowskiJ.T.Synthesis and antiviral activity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin).Journal of Medicinal Chemistry1978; 21: 742–746.
16.
KirsiJ.J., NorthJ.A., McKernanP.A., MurrayB.K., CanonicoP.G., HugginsJ.W., SrivastavaP.C., & RobinsR.K.Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.Antimicrobial Agents & Chemotherapy1983; 24: 353–361.
17.
BaldwinA., KingmanH., DarvilleM., FootA.B.M., GrierD., CornishJ.M., GouldenN., OakhillA., PamphilonD.H., StewardC.G., & MarksD.I.Outcome and clinical course of 100 patients with adenovirus infection following bone marrow transplantation.Bone Marrow Transplantation2000; 26: 1333–1338.
18.
La RosaA.M., ChamplinR.E., MirzaN., GajewskiJ., GiraltS., RolstonK.V., RaadI., JacobsonK., KontoyiannisD., EltingL., & WhimbeyE.Adenovirus infections in adult recipients of blood and marrow transplants.Clinical Infectious Diseases2001; 32: 871–876.
19.
SchleuningM., Buxbaum-ConradiH., JägerG., & KolbH-J. Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants.Hematology Journal2004; 5: 135–144.
20.
GilbertB.E., & KnightV.Biochemistry and clinical applications of ribavirin.Antimicrobial Agents & Chemotherapy1986; 30: 201–205.
21.
EchavarriaM., FormanM., van TolM.J.D., VossenJ.M., CharacheP., & KroesA.C.M.Prediction of severe disseminated adenovirus infection by serum PCR.Lancet2001; 358: 384–385.
22.
LankesterA.C., van TolM.J.D., ClaasE.C.J., VossenJ.M., & KroesA.C.M.Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients.Clinical Infectious Diseases2002; 34: 864–867.
